These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8289134)

  • 21. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects.
    Gordi T; Hou E; Kasichayanula S; Berner B
    Clin Ther; 2008 May; 30(5):909-16. PubMed ID: 18555937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
    Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination.
    Gisleskog PO; Hermann D; Hammarlund-Udenaes M; Karlsson MO
    Br J Clin Pharmacol; 1999 Jan; 47(1):53-8. PubMed ID: 10073740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects.
    Srinivas NR; Shyu WC; Gleason C; Schuster A; Greene DS; Barbhaiya RH
    Clin Pharmacol Ther; 1997 Oct; 62(4):408-16. PubMed ID: 9357392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses.
    Fujita T; Matsumoto Y; Kimura T; Yokota S; Sawada M; Majima M; Ohtani Y; Kumagai Y
    Br J Clin Pharmacol; 2002 Sep; 54(3):283-94. PubMed ID: 12236849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of nefazodone following multiple escalating oral doses in the dog.
    Shukla UA; Kaul S; Marathe PH; Pittman KA; Barbhaiya RH
    Eur J Drug Metab Pharmacokinet; 1992; 17(4):309-18. PubMed ID: 1301361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan.
    Barbhaiya RH; Buch AB; Greene DS
    Br J Clin Pharmacol; 1996 Nov; 42(5):573-81. PubMed ID: 8951188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.
    Purkins L; Wood N; Greenhalgh K; Allen MJ; Oliver SD
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):10-6. PubMed ID: 14616408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
    Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the steady-state pharmacokinetics of nefazodone after administration of 200 mg twice daily or 400 mg once daily in the morning or evening.
    Marathe PH; Lee JS; Greene DS; Barbhaiya RH
    Br J Clin Pharmacol; 1996 Jan; 41(1):21-7. PubMed ID: 8824689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects.
    Nirogi R; Mudigonda K; Bhyrapuneni G; Muddana NR; Goyal VK; Pandey SK; Palacharla RC
    Clin Drug Investig; 2018 May; 38(5):401-415. PubMed ID: 29380267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans.
    Matsushima N; Jakubowski JA; Asai F; Naganuma H; Brandt JT; Hirota T; Freestone S; Winters KJ
    Platelets; 2006 Jun; 17(4):218-26. PubMed ID: 16769599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers following single and multiple dose regimens.
    An G; Liu W; Katz DA; Marek GJ; Awni W; Dutta S
    Biopharm Drug Dispos; 2014 Oct; 35(7):417-29. PubMed ID: 25041811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administration.
    Scott G; Osborne SA; Greig G; Hartmann S; Ebelin ME; Burtin P; Rappersberger K; Komar M; Wolff K
    Clin Pharmacokinet; 2003; 42(14):1305-14. PubMed ID: 14606933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single- and multiple-dose mibefradil pharmacokinetics in normal and hypertensive subjects.
    Welker HA
    J Pharm Pharmacol; 1998 Sep; 50(9):983-7. PubMed ID: 9811158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
    Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
    Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
    Marzo A; Dal Bo L; Monti NC; Crivelli F; Ismaili S; Caccia C; Cattaneo C; Fariello RG
    Pharmacol Res; 2004 Jul; 50(1):77-85. PubMed ID: 15082032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor.
    Mallalieu NL; Rahimy MH; Crowley CA; Appleman JR; Smith PF; Freddo JL
    Clin Ther; 2014 Dec; 36(12):2047-2063.e3. PubMed ID: 25456558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
    Martin DE; Blum R; Doto J; Galbraith H; Ballow C
    Clin Pharmacokinet; 2007; 46(7):589-98. PubMed ID: 17596104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.